ArticleFrontiers in immunology2026
Diagnostic utility of targeted flow cytometry in genetically confirmed inborn errors of immunity: a 20-year single-center experience.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inborn errors of immunity (IEIs) are a heterogeneous group of genetic disorders in which timely diagnosis is essential for appropriate treatment and improved clinical outcomes. Although next-generation sequencing provides definitive molecular confirmation, it is often time-consuming, costly, and may not identify all disease-causing variants. We evaluated the diagnostic performance and diagnostic contribution of targeted flow cytometry (FCM) in genetically confirmed IEIs. Methods: We retrospectively analyzed 243 pediatric patients with genetically confirmed IEIs who underwent targeted flow cytometric evaluation at a single center between 2005 and 2025. Immunological evaluation included T-, B-, and NK-cell immunophenotyping, detailed T- and B-cell subset analysis, targeted protein expression assays, and neutrophil oxidative burst assessment using the dihydrorhodamine 123 assay. Molecular diagnoses were established by targeted gene panels, whole-exome sequencing, or Sanger sequencing. Results: The median age at symptom onset and molecular diagnosis was 12 and 70 months, respectively. Predominantly antibody deficiencies (31.7%) and syndromic combined immunodeficiencies (27.1%) were the most frequent IEI categories. Abnormal FCM findings were detected in 153 patients (63%) and predicted the underlying genetic category in 41 (27%). Diagnostic yield reached 100% in combined immunodeficiencies and 82.6% in immune dysregulation disorders, significantly exceeding that of syndromic combined immunodeficiencies and antibody deficiencies ( Conclusions: Targeted flow cytometry provides rapid functional evidence that complements molecular testing in patients with IEIs. Its integration into the initial diagnostic evaluation facilitates early disease stratification, guides targeted genetic investigations, and supports timely therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.